IL316406A - Lipid-modified relaxin B peptide chains and their medical use - Google Patents

Lipid-modified relaxin B peptide chains and their medical use

Info

Publication number
IL316406A
IL316406A IL316406A IL31640624A IL316406A IL 316406 A IL316406 A IL 316406A IL 316406 A IL316406 A IL 316406A IL 31640624 A IL31640624 A IL 31640624A IL 316406 A IL316406 A IL 316406A
Authority
IL
Israel
Prior art keywords
disease
medicament
manufacture
peptide
condition
Prior art date
Application number
IL316406A
Other languages
English (en)
Hebrew (he)
Inventor
Olivier Duclos
Stephane Illiano
Sergio Mallart
Claire Minoletti-Hochepied
Elisabetta Bianchi
Raffaele Ingenito
Paola Magotti
Alessia Santoprete
Original Assignee
Sanofi Sa
Olivier Duclos
Stephane Illiano
Sergio Mallart
Minoletti Hochepied Claire
Elisabetta Bianchi
Raffaele Ingenito
Paola Magotti
Alessia Santoprete
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Olivier Duclos, Stephane Illiano, Sergio Mallart, Minoletti Hochepied Claire, Elisabetta Bianchi, Raffaele Ingenito, Paola Magotti, Alessia Santoprete filed Critical Sanofi Sa
Publication of IL316406A publication Critical patent/IL316406A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL316406A 2018-01-31 2019-01-30 Lipid-modified relaxin B peptide chains and their medical use IL316406A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305094 2018-01-31
PCT/EP2019/052298 WO2019149782A1 (en) 2018-01-31 2019-01-30 Modified lipidated relaxin b chain peptides and their therapeutic use

Publications (1)

Publication Number Publication Date
IL316406A true IL316406A (en) 2024-12-01

Family

ID=61223862

Family Applications (2)

Application Number Title Priority Date Filing Date
IL276170A IL276170B2 (en) 2018-01-31 2019-01-30 Lipid-modified relaxin B peptide chains and their medical use
IL316406A IL316406A (en) 2018-01-31 2019-01-30 Lipid-modified relaxin B peptide chains and their medical use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL276170A IL276170B2 (en) 2018-01-31 2019-01-30 Lipid-modified relaxin B peptide chains and their medical use

Country Status (29)

Country Link
US (3) US10961295B2 (sr)
EP (1) EP3746467B1 (sr)
JP (1) JP7295871B2 (sr)
KR (1) KR102755938B1 (sr)
CN (1) CN111770934B (sr)
AR (1) AR114325A1 (sr)
AU (1) AU2019214358B2 (sr)
BR (1) BR112020014834A2 (sr)
CA (1) CA3089657A1 (sr)
CO (1) CO2020008308A2 (sr)
DK (1) DK3746467T3 (sr)
ES (1) ES3058633T3 (sr)
FI (1) FI3746467T3 (sr)
HR (1) HRP20260016T1 (sr)
IL (2) IL276170B2 (sr)
LT (1) LT3746467T (sr)
MA (1) MA52994A (sr)
MX (1) MX2020008096A (sr)
MY (1) MY199821A (sr)
NZ (1) NZ766762A (sr)
PH (1) PH12020551118A1 (sr)
PL (1) PL3746467T3 (sr)
PT (1) PT3746467T (sr)
RS (1) RS67606B1 (sr)
SG (1) SG11202006903WA (sr)
SI (1) SI3746467T1 (sr)
TW (1) TWI763972B (sr)
UY (1) UY38069A (sr)
WO (1) WO2019149782A1 (sr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
EP3746467B1 (en) 2018-01-31 2025-10-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
MX2024002335A (es) * 2021-08-23 2024-05-23 River 2 Renal Corp Combinacion de analogos de relaxina y vasopresina para el tratamiento de trastornos y afecciones renales.
IL311411A (en) 2021-09-15 2024-05-01 Viking Therapeutics Inc Preparations and methods for the treatment of metabolic and liver disorders
IL312731A (en) 2021-11-11 2024-07-01 Tectonic Therapeutic Inc Relaxin-2 fusion protein analogs and methods of using same
CN115998842B (zh) * 2022-09-02 2025-08-26 郑州大学第一附属医院 一种逆转肝星形细胞激活的仿生纳米药物及其应用
AU2024270919A1 (en) 2023-05-18 2026-01-15 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same
KR20250054870A (ko) * 2023-10-16 2025-04-24 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102348723A (zh) * 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
EP2359843A1 (en) * 2010-01-21 2011-08-24 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素（ｒｅｌａｘｉｎ）融合多肽類及其用途
US9382305B2 (en) * 2011-07-01 2016-07-05 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
EP2739647B1 (en) * 2011-08-04 2016-07-20 Relaxera GmbH & Co. KG i.G. c/o Immundiagnostik AG Process for preparing human relaxin-2
WO2013177529A1 (en) * 2012-05-24 2013-11-28 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
AU2014318579A1 (en) 2013-09-13 2016-04-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
WO2015157829A1 (en) * 2014-04-17 2015-10-22 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides
WO2015162485A1 (en) * 2014-04-22 2015-10-29 Txp Pharma Gmbh Peptide analogues with branched amino acid probe(s)
US10266578B2 (en) * 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
EP3746467B1 (en) 2018-01-31 2025-10-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
TW201934572A (zh) 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素ｂ鏈胜肽及其治療用途
TW202434620A (zh) * 2019-07-31 2024-09-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
MX2024002335A (es) * 2021-08-23 2024-05-23 River 2 Renal Corp Combinacion de analogos de relaxina y vasopresina para el tratamiento de trastornos y afecciones renales.

Also Published As

Publication number Publication date
PT3746467T (pt) 2026-01-13
MY199821A (en) 2023-11-23
CA3089657A1 (en) 2019-08-08
ES3058633T3 (en) 2026-03-12
FI3746467T3 (fi) 2026-01-16
SI3746467T1 (sl) 2026-02-27
UY38069A (es) 2019-08-30
MX2020008096A (es) 2020-09-24
US20210292387A1 (en) 2021-09-23
PH12020551118A1 (en) 2021-07-05
RS67606B1 (sr) 2026-01-30
IL276170B1 (en) 2024-11-01
US20240218042A1 (en) 2024-07-04
US10961295B2 (en) 2021-03-30
AU2019214358B2 (en) 2023-05-25
EP3746467B1 (en) 2025-10-08
HRP20260016T1 (hr) 2026-02-27
SG11202006903WA (en) 2020-08-28
PL3746467T3 (pl) 2026-04-13
US11725036B2 (en) 2023-08-15
CN111770934A (zh) 2020-10-13
IL276170B2 (en) 2025-03-01
DK3746467T3 (da) 2026-01-12
JP2021512099A (ja) 2021-05-13
AU2019214358A1 (en) 2020-08-20
KR20200116085A (ko) 2020-10-08
KR102755938B1 (ko) 2025-01-20
BR112020014834A2 (pt) 2020-12-08
JP7295871B2 (ja) 2023-06-21
RU2020126210A (ru) 2022-02-28
US20190233494A1 (en) 2019-08-01
EP3746467A1 (en) 2020-12-09
WO2019149782A1 (en) 2019-08-08
CO2020008308A2 (es) 2020-10-30
TW201940505A (zh) 2019-10-16
MA52994A (fr) 2021-05-05
CN111770934B (zh) 2024-10-18
LT3746467T (lt) 2026-01-26
NZ766762A (en) 2026-03-27
IL276170A (en) 2020-09-30
TWI763972B (zh) 2022-05-11
AR114325A1 (es) 2020-08-19

Similar Documents

Publication Publication Date Title
US12478617B2 (en) Lipidated peptide inhibitors of interleukin-23 receptor
FI3746467T3 (fi) Muutetut lipidoidut relaksiinin b-ketjun peptidit ja niiden terapeuttinen käyttö
JP5315372B2 (ja) Ｃｘｃｒ４拮抗薬およびその用途
AU2022310354A1 (en) Peptide inhibitors of interleukin-23 receptor
JP2015533833A5 (sr)
JP2021512099A5 (sr)
JP2016515620A5 (sr)
IL262805B2 (en) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
IL275188B2 (en) Peptides for treatment and prevention of nonalcoholic fatty liver disease and fibrosis
JP2016518351A5 (sr)
JPWO2009142307A1 (ja) 目的ペプチドの血漿中半減期延長作用を有するペプチド
JP2025186365A (ja) α４β７インテグリン拮抗薬で炎症性腸疾患を治療するための方法
KR20170028307A (ko) α4β7 인테그린 티오에테르 펩티드 길항제
JP6158097B2 (ja) 炎症を抑制するためのペプチド
CA2945838C (en) Modified relaxin b chain peptides
KR20160009008A (ko) 심부전과 관련된 위험 및 이와 관련된 인자를 감소시키는 방법
JP2022545554A (ja) Ｑ－ｅｒペプチド
RU2016110153A (ru) Новые пептиды и их аналоги для применения при лечении мукозита полости рта
JP2024532403A5 (sr)
JPH02174798A (ja) 細胞接着活性コア配列の繰り返し構造からなるポリペプチド
CN107001440A (zh) 稳定化的肾上腺髓质素衍生物及其用途
JP2017524675A5 (sr)
JP2020515283A5 (sr)
JP2008514588A5 (sr)
JP5687266B2 (ja) 大動脈線維症の治療のための組成物および方法